The U.S. initial public offering market is set to restart after the conclusion of the longest government shutdown in history, which had paused SEC operations. For the week ahead, the calendar is led by three distinct deals: a large regional bank seeking a major exchange uplisting, a high-growth Christian technology platform, and a speculative biotech firm. This diverse slate will be an early test of investor interest as the stock market looks to regain its footing.
The Deals on Deck
The week’s largest offering comes from Central Bancompany (CBC), a Missouri-based “super-community bank” currently listed on the OTC market. The bank, which operates 156 full-service branches across Missouri and four other states, is seeking to raise $400 million in its uplisting. It is joined by Gloo Holdings (GLOO), a faith-focused technology platform that provides digital tools to churches and Christian organizations. Gloo aims to raise $100 million. A smaller, more speculative deal from Israeli regenerative medicine company Regentis Biomaterials (RGNT) is also tentatively scheduled, seeking $11 million.
IPO Details
Central Bancompany plans to list on the Nasdaq under its current ticker, CBC. The bank is offering 17.8 million shares at a price range of $21.00 to $24.00, which would command a substantial $5.4 billion market capitalization at the midpoint. The deal is being led by top-tier underwriters, Morgan Stanley and Keefe Bruyette Woods. Gloo Holdings intends to list on the Nasdaq under the ticker GLOO, offering 9.1 million shares in a $10.00 to $12.00 range. At the midpoint, this would give the company an $801 million market cap, with Roth Capital managing the deal.
Market Context & Opportunities
This week’s offerings present a clear contrast in investment theses. Central Bancompany represents a traditional value and stability play. Its primary strength lies in its low cost of deposits, which allows it to generate a strong net interest margin—a highly attractive quality in the current financial environment. This IPO is a strategic uplisting designed to attract a wider pool of institutional investors and improve liquidity for its shares. On the other hand, Gloo Holdings is a high-growth story. It operates in a unique and often-overlooked vertical market, having already amassed 57,000 paying customers, demonstrating a clear demand for its services.
Risks & Challenges
Despite their strengths, both lead deals carry notable risks. For Central Bancompany, the primary concern for prospective investors will be its growth trajectory. The bank’s asset growth was minimal, at just 1% in 2024, which may deter investors seeking expansion over simple stability. For Gloo Holdings, scrutiny will fall on its growth strategy. While its expansion has been strong, it has relied heavily on acquisitions to fuel that growth, raising questions about its organic customer acquisition and long-term profitability. Regentis Biomaterials carries the highest risk, as its lead candidate is still in pivotal trials in the US, making it a binary bet on clinical success.
Closing Paragraph
As the market debut for these companies approaches, this first post-shutdown week will serve as a crucial barometer for the IPO market. It will test whether investor interest is stronger for the proven, stable, and profitable model of a regional bank like Central Bancompany, or for the high-growth, niche-market narrative of a tech platform like Gloo. The reception these deals receive will provide a clear signal on the market’s risk appetite heading into the end of the year.
